Search results for "Colore"
showing 10 items of 1250 documents
O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C stu…
2021
PD-8 Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety resu…
2020
Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer
2019
Gene signatures in CRC and liver metastasis
2011
Colorectal cancer (CRC) is one of the most common causes of cancer-related death with a worldwide incidence of almost a million cases annually in both males and females. The accelerated decrease in CRC incidence rates from 1998 to 2006 largely reflects the advances in diagnosis and treatment that have enabled to detect and remove precancerous polyps. However, the screening technology has not resulted in major improvements in the prognosis of patients with advanced cancer and the liver metastasis remains the major cause of death in CRC. About 25% of patients have detectable liver metastasis at diagnosis, that are classified as “synchronous” lesions and approximately 70% of patients develop a…
P021 Heat working environment and risk of breast, chronic lymphocytic leukaemia, colorectal, prostate, and stomach cancer in the MCC-spain case contr…
2016
Occupational exposure to heat can affect the absorption of carcinogenic chemicals into the body, and the metabolism of sexual hormones. We explored the association between occupational exposure to heat and breast, chronic lymphocytic leukaemia, colorectal, prostate, and stomach cancer in the MCC-Spain population based case-control study. Methods The analyses were based on 3047 controls, and 1499 breast, 1539 colorectal, 332 LLC, 1070 prostate, and 382 stomach cancer cases. Heat working environment from either natural or artificial sources was assessed with the MatEmEsp job-exposure matrix. Logistic regression models accounting for education, sex, geographic area, BMI (colorectal, prostate),…
CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2…
2021
Adjuvant colon cancer (CC) therapy and survival have greatly evolved over the last decades. Research shifted towards a more biological tumour understanding and unlocked new therapies and disease mo...
Programmed colorectal cancer screening decreases incidence and mortality
2019
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer- related deaths in the world (1). Detecting and removing precancerous lesions or detecting tumors in early stages through endoscopy decreases CRC mortality (2). Randomized controlled trials (RCTs) have shown that CRC screening based on guaiac fecal occult blood testing (gFOBT) and flexible sigmoidoscopy is effective in reducing incidence and mortality rates of CRC (3).
Cetuximab: clinical results in colorectal cancer
2007
In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.
2010
Isolated Metachronous Splenic Metastasis from Colon Cancer: Possible Explanations for This Rare Entity
2017
The incidence of splenic metastases secondary to colorectal cancer is very low; these lesions have been more frequently reported as secondary to breast, lung, and ovarian cancer. Splenic metastases are particularly common in melanoma; their incidence has been reported as being as high as 34% at autopsy [1]. Most cases of secondary splenic metastases have been described in patients with tumors of the left colon while only few cases being reported as originating from right colon tumors (Table 1). The finding of a splenic mass in the absence of a history of malignancy suggests a primary lesion (lymphoma, hematoma, etc.), while a history of oncological disease raises the possibility of a second…